The effects of vitamin and mineral supplementation on women with gestational diabetes mellitus

Dandan Li, Zixin Cai, Zhenhong Pan, Yan Yang and Jingjing Zhang*

Abstract

Background: The effects of vitamin and mineral supplementation on women with gestational diabetes mellitus (GDM) have not been well established. We conduct a meta-analysis to evaluate the effects of vitamin and mineral supplementation on glycemic control, inflammation and oxidative stress for women with GDM.

Methods: A systematic search of randomized controlled trials (RCTs) was conducted from PubMed, Embase, Web of Science and Cochrane Library up to July, 2020. Various results were pooled by using Review manager 5.3 and Stata 12.0. Mean difference (MD) with 95% confidence interval (CI) was estimated. Heterogeneity between studies was assessed by I-squared ($I^2$) tests.

Results: Six hundred ninety-eight patients from 12 trials were included in our meta-analysis. Magnesium, zinc, selenium, calcium, vitamin D and E (alone or in combination) were found to significantly improve glycemic control in women with GDM compared to those receiving placebos: fasting plasma glucose (FPG) (MD = - 9.02; 95% CI: - 12.09, - 5.96; $P < 0.00001$), serum insulin (MD = - 4.33; 95% CI: - 5.35, - 3.32; $P < 0.00001$), homeostasis model assessment-insulin resistance (HOMA-IR) (MD = - 1.34; 95% CI: - 1.60, - 1.07; $P < 0.00001$), and homeostasis model of assessment for $\beta$ cell function (HOMA-B) (MD = - 15.58; 95% CI: - 23.70, - 7.46; $P = 0.0002$). Vitamin and mineral supplementation was found to attenuate inflammation and oxidative stress through decreasing high-sensitivity C-reactive protein (hs-CRP) (MD = - 1.29; 95% CI: - 1.82, - 0.76; $P < 0.00001$), malondialdehyde (MDA) (MD = - 0.71; 95% CI: - 0.97, - 0.45; $P < 0.00001$), and increasing total antioxidant capacity (TAC) (MD = 45.55; 95% CI: 22.02, 69.08; $P = 0.0001$).

Conclusions: This meta-analysis shows that vitamin and mineral supplementation significantly improved glycemic control, attenuated inflammation and oxidative stress in women with GDM.

Keywords: Gestational diabetes mellitus, Vitamins, Minerals, Glycemic control, Inflammation, Oxidative stress

Background

Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance with onset or first recognition during pregnancy [1]. Many risk factors, including obesity, gestational age and genetic background, contribute to the development of GDM [2]. The prevalence of GDM was reported approximately 15 to 20% worldwide [3]. Hyperglycemia during pregnancy is associated with adverse outcomes of both mother and offspring [4]. Women with a history of GDM are at increased risk of developing insulin resistance syndrome (IRS) and cardiovascular disease (CVD) later in life [4, 5].

* Correspondence: doctorzhangjj@csu.edu.cn
National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Chronic low-grade inflammation is related to many known risk factors of GDM [6]. Increased degrees of inflammation during early pregnancy are associated with increased risk of GDM and the development of hyperglycemia [7]. In addition, the presence of oxidative stress has been reported in GDM [8–10], and the antioxidant status in women with GDM was down-regulated [11]. Oxidative stress plays important roles both in the pathogenesis and complications of GDM, supplementary therapy with antioxidants might help to reverse the oxidative status and improve the neonatal outcome [12, 13]. Zinc deficiency [14], hypomagnesemia [15] are common features in diabetes, and low circulating levels of vitamin D [16], vitamin E [11], and magnesium [17] have been found in women with GDM. Many reports showed that vitamin and mineral supplementation, such as vitamin D [18], vitamin E [13], magnesium [15, 19], and selenium [20] may regulate glucose metabolism and have beneficial roles in anti-inflammatory and anti-oxidative stress.

Nowadays, there is a growing interest to use vitamin and mineral supplementation during pregnancy, especially for women with GDM. Vitamin D is the most commonly used nutrient in the treatment of GDM, but the effect of vitamin D supplementation on glycemic control in GDM remains controversial. Some studies showed that vitamin D supplementation had beneficial effects on glycemia in women with GDM [18]. However, other studies showed that vitamin D supplementation had no significant effect on fasting plasma glucose (FPG) or fasting blood glucose (FBG) level in patients with GDM [21]. The role of selenium in glucose control in GDM was also inconsistent. A clinical trial showed that 200 μg selenium supplements for 6 weeks significantly reduced FPG and serum insulin levels in GDM patients [20]. However, another clinical trial showed that 100 μg selenium supplements for 12 weeks has no significant effect in regulating glucose homeostasis in women with GDM [22]. Studies on the effects of vitamin D and other nutritional supplementation on biomarkers of inflammation and oxidative stress in patients with GDM also have inconsistent results [18, 23, 24]. It was reported that vitamin D supplementation had no significant effect on hs-CRP, plasma TAC, and total GSH [18]. However, other studies showed that vitamin D or vitamin D-calcium co-supplementation had beneficial effects on biomarkers of inflammation and oxidative stress [23, 24]. Thus, this meta-analysis was conducted to evaluate the effects of vitamin and mineral supplementation, especially vitamin and mineral co-supplementation, on glycemic control, inflammation and oxidative stress in GDM patients.

Methods

Search strategy and study selection

This systematic literature search was done according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [25]. PubMed, Embase, Web of Science and Cochrane Library of RCTs were searched up to July, 2020. Search terms include Medical Subject Headings (MeSH) and keywords related to GDM, vitamins, minerals, micronutrients, glycemic control, inflammation and oxidative stress. The details of the search strategy are reported in the supplementary information. The search was limited to publications in English. DL and ZP did the literature searches, and discrepancies were resolved by discussion with a third author (ZC).

Eligibility criteria

Eligible articles were considered if they met the following criteria: (1) Participants: women with GDM; (2) Interventions: vitamin supplementation, or mineral supplementation, or vitamin and mineral co-supplementation; (3) Controls: placebo treatment; (4) Outcomes: at least one of the following outcomes was reported, FPG, serum insulin, homeostasis model assessment-insulin resistance (HOMA-IR), homeostasis model of assessment for β cell function (HOMA-B), high-sensitivity C-reactive protein (hs-CRP), total antioxidant capacity (TAC), glutathione (GSH), and malondialdehyde (MDA); (5) Studies: randomized controlled trials (RCTs). Trials were excluded if patients require substitute treatments (such as insulin and metformin et al.), or treatment was medications other than vitamins, minerals or placebo. We also excluded trials without accessible data or full text, or carried out after delivery.

Data extraction

Data extraction and analysis from included studies were performed by two authors independently (DL and ZP), and conflicts were resolved by a third author (YY). The following information was extracted: first author, publication year, agent, number of participants, dosage, follow-up duration, trial registration number, study location, clinical phase, and outcomes of interest.

Study quality and risk of Bias assessment

The Cochrane Collaboration’s risk of bias tool was used to assess the risk of bias, including the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. The risk of bias was judged as low, high, or unclear, according to the criteria of Cochrane Handbook.
Publication Bias assessment
Funnel plot and Egger’s test were used to assess the publication bias and tested for statistical significance. *P* value less than 0.1 was considered significant.

Statistical analyses
Results were presented as mean difference (MD) with 95% confidence interval (CI). Heterogeneity among studies was estimated by I-squared ($I^2$) tests. *P* value < 0.1 and $I^2 > 50\%$ indicated statistical heterogeneity, and random-effects models were used in meta-analysis; otherwise, fixed-effects models were used. Sensitivity analyses were also performed to examine the effect of each trial on the overall analysis. All statistical analyses were done with Review manager 5.3 and Stata 12.0.

Results
Included studies and baseline characteristics
Our initial search found 1195 potentially relevant articles. After screening, 12 studies were included for meta-analysis [18, 20, 23, 24, 26–33]. The details of study identification and selection were shown in Fig. 1. Table 1 lists key characteristics of the RCTs. Trials included were published between 2013 and 2019. Those 12 selected studies included 698 randomized participants, and all of them were conducted in Iran. Patients included were in the age range of 18–40, and all reported GDM screening was conducted between 24 weeks and 28 weeks gestation. All trials gave vitamin and mineral supplementation orally. Types, doses, dose regimens, and duration of vitamin and mineral supplementation were as follows: magnesium (100–250 mg), zinc (4–233 mg), selenium (200 μg), calcium (400–1000 mg), and vitamin E (400 IU) every day for 6 weeks, vitamin D (200–50,000 IU) every day or every 2 or 3 weeks for 6 weeks. Magnesium, zinc, selenium, calcium, vitamin D or E was given separately or in different combinations: magnesium and vitamin E; zinc and vitamin E; calcium and vitamin D; magnesium, zinc, calcium and vitamin D. All trials used placebo as control intervention.

Risk of bias of individual studies
The quality of the included trails was assessed according to the criteria of Cochrane Handbook, and the results of risk of bias and risk of bias summary are summarized in Fig. 2. Among the 12 trials, 8 were judged to be at low risk of bias and 4 as being at unclear risk of bias. Unclear risks were related to attrition bias and other bias.

Meta-analysis
The effects of vitamin and mineral supplementation on glycemic control
Ten RCTs examined the effects of vitamin and mineral supplementation on FPG level among patients with GDM. The pooled results indicated that FPG level decreased significantly following vitamin and mineral supplementation (MD = - 9.02; 95% CI: - 12.09, - 5.96; *P* < 0.00001) (Fig. 3a). There was significant heterogeneity among studies ($I^2 = 79\%$; *P* < 0.00001). Subgroup analysis was performed according to the type of interventions, and there are four subgroups including vitamin D and minerals, vitamin E and minerals, vitamin D, and minerals. Taking individual vitamin and mineral supplementation (50,000 IU vitamin D every 3 weeks, 200 μg/d selenium, 250 mg /d magnesium or 233 mg/d zinc) could significantly decrease the FPG level in GDM patients (Fig. 3b). Similar results were found in combined vitamin and mineral supplementation: 400 IU/d vitamin E plus either 250 mg/d magnesium or 233 mg/d zinc (MD = - 4.46; 95% CI: - 6.84, - 2.08; *P* = 0.0002) (Fig. 3b), 100 mg magnesium, 4 mg zinc, 400 mg calcium plus 200 IU vitamin D supplementation twice a day, or 1000 mg calcium/d plus 50,000 IU vitamin D3 every 3 weeks (MD = - 9.53; 95% CI: - 17.63, - 1.43; *P* = 0.02) (Fig. 3b). Sensitivity analysis of FPG showed that the removal of any given named study, the pooled results were largely unchanged (Fig. 3c).

Vitamin and mineral supplementation was found to significantly reduce serum insulin levels (n = 8; MD = - 4.33; 95% CI: - 5.35, - 3.32; *P* < 0.00001) (Fig. 4a). Subgroup analysis according to type of interventions removed the heterogeneity between studies in serum insulin (Fig. 4b).
HOMA-IR level decreased significantly following vitamin and mineral supplementation ($n = 8$; MD = - 1.34; 95% CI: - 1.60, - 1.07; $P < 0.00001$) (Fig. 5a), with low heterogeneity among studies. Subgroup analysis according to the type of interventions removed the heterogeneity between studies in HOMA-IR (Fig. 5b), and the pooled results were largely unchanged.

Vitamin and mineral supplementation significantly reduced the HOMA-B levels ($n = 5$; MD = - 15.58; 95% CI: - 23.70, - 7.46; $P = 0.0002$) (Fig. 6a). Subgroup analysis showed that mineral supplementation, such as 200 μg selenium/d, 250 mg magnesium/d, or 233 mg zinc gluconate/d, could significantly reduce the HOMA-B levels (MD = - 23.73; 95% CI: - 34.53, - 12.94; $P < 0.0001$), while vitamin D, vitamin D and calcium co-supplementation have no significant effect on HOMA-B levels (Fig. 6b).

**The effects of vitamin and mineral supplementation on inflammatory markers**

Figure 7a shows the forest plots for inflammatory markers hs-CRP. The results showed that vitamin and mineral supplementation significantly reduced the hs-CRP level ($n = 7$; MD = - 1.29; 95% CI: - 1.82, - 0.76; $P < 0.00001$), with no heterogeneity among the studies ($I^2 = 0\%$, heterogeneity $P = 0.80$). However, subgroup analysis according to the type of interventions showed that vitamin D and minerals co-supplementation has no significant effect on hs-CRP levels with moderate heterogeneity between studies (Fig. 7b).

**The effects of vitamin and mineral supplementation on biomarkers of oxidative stress**

TAC is considered to be an indicator of the oxygen radical absorbance capacity. Vitamin D, minerals and vitamin D plus mineral co-supplementation significantly increased TAC level compared with placebo (MD = 45.55; 95% CI: 22.02, 69.08; $P = 0.0001$) (Fig. 8a), with low heterogeneity among studies ($I^2 = 25\%$, heterogeneity $P = 0.24$). Subgroup analysis of TAC according to the type of interventions showed that mineral subgroup, such as selenium, magnesium, or zinc, could significantly increase TAC level, while vitamin D alone or vitamin D and mineral co-supplementation has no significant effect on TAC levels, with moderate heterogeneity among studies (Fig. 8b).

GSH is an endogenous antioxidant, but vitamin and mineral supplementation did not significantly affect GSH level (MD = 30.66; 95% CI: - 8.31, 69.64; $P = 0.12$) (Fig. 9a), and there was moderate heterogeneity among studies ($I^2 = 62\%$, $P = 0.02$). Subgroup analysis (Fig. 9b) and sensitivity analysis (Fig. 9c) of GSH according to the type of interventions didn’t change the results.

Vitamin and mineral supplementation significantly reduced MDA (MD = - 0.71; 95% CI: - 0.97, - 0.45; $P < 0.00001$) (Fig. 10a), an indicator of lipid peroxide formation, and no heterogeneity was found among the studies ($I^2 = 0\%$, heterogeneity $P = 0.95$). In subgroup analysis according to the type of interventions, the effects of vitamin and mineral supplementation on MDA levels stay the same (Fig. 10b).

**Publication bias**

No significant publication bias was found for the effect of vitamin and mineral supplementation on all eight outcomes (Fig. S1).

**Discussion**

In this meta-analysis, we pooled the results of high-quality RCTs in women with GDM to assess the effects...
Fig. 2 Risk of bias a and risk of bias summary b. In Fig. 2a, green represents a low risk of bias, while yellow represents unclear risk of bias. In Fig. 2b, + represents a low risk of bias, while ? represents unclear risk of bias.
**Fig. 3** Forest plot of pooled MD and sensitivity analysis in FPG of studies included. **a** Meta-analysis of the effects of vitamin and mineral supplementation on FPG in women with GDM (random-effects model); **b** The forest plot of FPG in subgroup analysis defined by the type of interventions (random-effects model); **c** Sensitivity analysis in FPG of studies included. Mean difference, MD; Fasting plasma glucose, FPG; gestational diabetes mellitus, GDM.

**Fig. 4** Forest plot of pooled MD in serum insulin of studies included. **a** Meta-analysis of the effects of vitamin and mineral supplementation on serum insulin in women with GDM (fixed-effects model); **b** The forest plot of serum insulin in subgroup analysis defined by the type of interventions (random-effects model). Mean difference, MD; gestational diabetes mellitus, GDM.
of vitamin and mineral supplementation vs placebo on glycemic control, biomarkers of inflammation and oxidative stress. Due to the close metabolism regulation between vitamins and minerals and data on the effects of vitamin and mineral co-administration on glucose regulation, inflammation and oxidative stress markers in women with GDM are scarce, we specifically included vitamin and mineral co-administration trails in this meta-analysis. And in order to have more reliable results and decrease the heterogeneity between different studies, we didn’t include trials if patients require substitute treatments (such as insulin and metformin et al.) or carried out after delivery, since both substitute treatments and delivery can affect glycemic status. Our findings

Fig. 5 Forest plot of pooled MD in HOMA-IR of studies included. a Meta-analysis of the effects of vitamin and mineral supplementation on HOMA-IR in women with GDM (fixed-effects model); b The forest plot of HOMA-IR in subgroup analysis defined by the type of interventions (random-effects model). Mean difference, MD; Homeostasis model assessment-insulin resistance, HOMA-IR; gestational diabetes mellitus, GDM.
demonstrated that vitamin and mineral supplementation, magnesium, zinc, selenium, calcium, vitamin D and E (alone or in combination), significantly improved glycemic control, attenuated inflammation and oxidative stress in women with GDM through decreasing serum FPG, insulin, HOMA-IR, HOMA-B, hs-CRP and MDA levels, and increasing TAC levels.

Vitamin and mineral supplementation improved glycemic control in GDM and related mechanism
Findings from this meta-analysis demonstrated that vitamin and mineral supplementation had a significant effect on serum insulin and blood glucose parameters. Subgroup analysis of the interventions showed that single mineral or vitamin D, or combined vitamin D/E and mineral supplementation all worked well on glycemic control. We found that vitamin D, magnesium and zinc has the potential role to promote glycemic control in diabetes patients. The dosages of vitamin D might be a reason of high heterogeneity of FPG in vitamin D and minerals group, 50,000 IU vitamin D every 3 weeks plus 1000 mg calcium per day worked better than 200 IU vitamin D supplementation plus minerals (100 mg magnesium, 4 mg zinc and 400 mg calcium) twice a day. Although different doses of vitamin D supplementation, ranging from 200 to 4000 IU daily for 12.5 days, had no effect on FPG level in women with GDM, higher doses of vitamin D significantly improved insulin resistance [5]. Vitamin D can activate
the transcription of insulin receptor gene to promote glucose oxidation through the phosphoinositide 3-kinase (PI3-K) pathway \[34\]. Vitamin E plays an important role in regulating glucose metabolism through improving insulin action by upregulation of GSH/GSSG ratio and magnesium concentration \[13\]. Magnesium can regulate glucose and insulin metabolism by affecting the tyrosine kinase activity of insulin receptor, and help transport glucose into the cells via glucose transporter protein activity 4 (GLUT4) \[35\]. Zinc can regulate insulin signaling through PI3-K/Akt pathway and help transport GLUT4 to the cell membrane \[14\].

**Vitamin and mineral supplementation relieves inflammation and possible mechanisms in GDM**

Pregnant women with obesity or GDM have increased maternal inflammation and elevated hs-CRP compared to normal pregnant women, and suppression of inflammation helps improving pregnancy outcomes and maternal complications. Our meta-analysis showed that the supplementation of vitamin and mineral could significantly reduce the serum hs-CRP level in GDM patients. Subgroup analysis of treatments demonstrated that mineral supplementation, including zinc, magnesium, and selenium, was more significant than vitamin D and mineral supplementation in reducing hs-CRP level. Vitamin
D, zinc and selenium can decrease the concentration of inflammatory cytokines through down-regulation of nuclear transcription factor κB (NF-κB), a key regulator of genes involved in inflammation [14, 36]. Magnesium may decrease inflammatory response via regulation the intracellular calcium concentration and inhibition the NF-κB signaling pathway [37, 38].

**Underlying mechanisms of vitamin and mineral supplementation on oxidative stress in GDM**

Oxidative stress plays a key role in the development of diabetes mellitus [39]. Many kinds of vitamins and minerals have antioxidant activity and may have beneficial role in diabetes. Our meta-analysis showed a benefit effect of vitamin and mineral supplementation, including vitamin D, Calcium plus vitamin D, zinc and magnesium, on alleviating oxidative stress status in GDM patients through improving TAC levels, and reducing MDA levels. Vitamin D can increase GSH formation by upregulation of glutamate cysteine ligase (GCLC) and glutathione reductase (GR), which recycles oxidized GSSG to GSH to scavenge excessive ROS [40]. Magnesium can influence the activities of mitochondrial electron transport chain and ROS production [41]. Zinc is essential for the activity of superoxide...
dismutase (SOD), which plays an important role in redox balance, and may play antioxidant effect by decreasing ROS production [14].

There are interactions between different vitamins and minerals. Zinc can regulate the release of calcium by acting on zinc-sensing receptor [42], vitamin D affects insulin secretion by regulating plasma calcium [43], vitamin E can improve glucose disposal through the upregulation of magnesium concentration [13], magnesium is involved in the synthesis, transport and activation of

---

**Fig. 9** Forest plot of pooled MD and sensitivity analysis in GSH of studies included. a Meta-analysis of the effects of vitamin and mineral supplementation on GSH in women with GDM (random-effects model); b The forest plot of GSH in subgroup analysis defined by the type of interventions (random-effects model); c Sensitivity analysis in GSH of studies included. Mean difference, MD; Glutathione, GSH; gestational diabetes mellitus, GDM

| Study or Subgroup | Experimental | Control | Mean Difference IV, Fixed, 95% CI |
|-------------------|--------------|---------|----------------------------------|
| asemi 2014        | 0.06         | 0.66    | 28 0.93 2 28 11.2% -0.87 [-1.65, -0.09] |
| asemi 2015-2      | -0.5         | 1.6     | 35 0.3 1.2 35 15.6% -0.80 [-1.46, -0.14] |
| Jamiliani 2019    | -0.3         | 0.3     | 30 0.3 1.1 30 41.1% -0.60 [-1.01, -0.19] |
| karamali 2016     | -0.3         | 1.9     | 25 0.6 1.4 25 8.0% -0.90 [-1.83, 0.03] |
| razavi 2017       | -0.2         | 0.5     | 30 0.5 1.4 30 24.2% -0.70 [-1.23, -0.17] |
| Total (95% CI)    | 148          | 148     | 100.0% -0.71 [-0.97, -0.45] |

Test for overall effect: Z = 5.32 (P < 0.00001)

---

**Fig. 10** Forest plot of pooled MD in MDA of studies included. a Meta-analysis of the effects of vitamin and mineral supplementation on MDA in women with GDM (fixed-effects model); b The forest plot of MDA in subgroup analysis defined by the type of interventions (random-effects model). Mean difference, MD; Malondialdehyde, MDA; gestational diabetes mellitus, GDM

| Study or Subgroup | Experimental | Control | Mean Difference IV, Random, 95% CI |
|-------------------|--------------|---------|----------------------------------|
| razavi 2017       | -0.2         | 0.5     | 30 0.5 1.4 30 24.2% -0.70 [-1.23, -0.17] |
| Subtotal (95% CI) | 60           | 60      | 23.6% -0.83 [-1.37, -0.30] |

Heterogeneity: Tau² = 0.00, Chi² = 3.36, df = 1 (P = 0.07); η² = 0%
Test for overall effect: Z = 3.57 (P = 0.002)

---

**Table 3.8.1 Vitamin D**

| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|-------------------|------|----|-------|------|----|-------|--------|----------------------------------|
| razavi 2017       | -0.2 | 0.5 | 30    | 0.5  | 1.4| 30    | 24.2%  | -0.70 [-1.23, -0.17] |
| Subtotal (95% CI) | 30   | 30 | 100.0% | 24.2% |    |       |        | -0.70 [-1.23, -0.17] |

Heterogeneity: Not applicable
Test for overall effect: Z = 2.58 (P = 0.010)

---

**Table 3.8.2 Minerals**

| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|-------------------|------|----|-------|------|----|-------|--------|----------------------------------|
| asemi 2015-2      | -0.5 | 1.6 | 35    | 0.3  | 1.2| 35    | 15.6%  | -0.80 [-1.46, -0.14] |
| karamali 2016     | -0.3 | 1.9 | 25    | 0.6  | 1.4| 25    | 8.0%   | -0.90 [-1.83, 0.03] |
| Subtotal (95% CI) | 60   | 60 | 100.0% | 23.6% |    |       |        | -0.83 [-1.37, -0.30] |

Heterogeneity: Tau² = 0.00, Chi² = 0.03, df = 1 (P = 0.88); η² = 0%
Test for overall effect: Z = 3.57 (P = 0.002)

---

**Table 3.8.3 Vitamin D and minerals**

| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI |
|-------------------|------|----|-------|------|----|-------|--------|----------------------------------|
| asemi 2014        | 0.06 | 0.66| 20    | 0.93 | 2  | 20    | 11.2%  | -0.07 [-1.65, -0.08] |
| Jamiliani 2019    | -0.3 | 0.3 | 30    | 0.3  | 1.1| 30    | 41.1%  | -0.60 [-1.01, -0.19] |
| Subtotal (95% CI) | 58   | 58 | 100.0% | 52.3% |    |       |        | -0.66 [-1.02, -0.30] |

Heterogeneity: Tau² = 0.00, Chi² = 0.36, df = 1 (P = 0.55); η² = 0%
Test for overall effect: Z = 3.57 (P = 0.0004)

---

Total (95% CI)

| Study or Subgroup | Mean | SD | Total | Mean Difference IV, Random, 95% CI |
|-------------------|------|----|-------|----------------------------------|
| razavi 2017       | -0.2 | 0.5 | 30    | -0.71 [-0.97, -0.45] |
| Subtotal (95% CI) | 60   | 60 | 100.0% | -0.71 [-0.97, -0.45] |

Heterogeneity: Tau² = 0.00, Chi² = 0.66, df = 4 (P = 0.95); η² = 0%
Test for overall effect: Z = 5.32 (P < 0.00001)
Test for subgroup differences: Chi² = 0.28, df = 2 (P = 0.87); η² = 0%
vitamin D [44]. Because of the possible interactions between different vitamins and minerals, further studies are necessary to assess whether the combination of vitamins and minerals is more effective than a single vitamin or mineral on GDM.

Limitations of our study
There are several limitations in our meta-analysis. First, the diversity of vitamin and mineral types and combinations make it challenging to perform subgroup analysis for all treatments. Second, all included trials were from Iran, and there was a lack of data from other countries. Finally, since GDM usually diagnosed between 24- and 28-week gestation, we didn’t include studies last more than 3 months to see the effect on postpartum outcomes.

Conclusion
In conclusion, our meta-analysis suggests a beneficial role of single or vitamin and mineral co-supplementation on biomarkers of glycemic control, inflammation and oxidative stress in women with GDM. In the future, more large-scale and longer duration studies of vitamin and mineral supplementation, especially vitamin and mineral co-supplementation, are needed to demonstrate their effect on glycemic control, anti-inflammatory and antioxidative effects in women with GDM.

Abbreviations
GDM: Gestational diabetes mellitus; T2D: Type 2 diabetes; CVD: Cardiovascular disease; IRS: Insulin resistance syndrome; FPG: Fasting plasma glucose; FBG: Fasting blood glucose; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; MeSH: Medical Subject Headings; HOMA-IR: Homeostasis model assessment-insulin resistance; HOMA-B: Homeostasis model of assessment for β cell function; hs-CRP: High-sensitivity C-reactive protein; TAC: Total antioxidant capacity; GSH: Glutathione; MDA: Malondialdehyde; RCTs: Randomized controlled trials; MD: Mean difference; CI: Confidence interval; I²: I-squared; PI3: P110; K: Phosphoinositide 3-kinase; GLUT4: Glucose transporter protein activity 4; NF-κB: Nuclear transcription factor κB; GCLC: Glutamate cysteine ligase; GR: Glutathione reductase; SOD: Superoxide dismutase

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12902-021-00712-x.

Additional file 1: Full search strategy in database. Search strategy of Pubmed (A), Embase (B), Web of Science (C) and Cochrane Library (D).

Additional file 2: Figure S1 Funnel plot for publication bias test of included studies for FPG (A), serum insulin (B), HOMA-IR (C), HOMA-B (D), hs-CRP (E), TAC (F), GSH (G), and MDA (H). Fasting plasma glucose, FPG; Homeostasis model assessment-insulin resistance, HOMA-IR; Homeostasis model of assessment for β cell function, HOMA-B; High-sensitivity C-reactive protein, hs-CRP; Total antioxidant capacity, TAC; glutathione, GSH; Malondialdehyde, MDA

Acknowledgements
Not applicable.

Authors’ contributions
DL planned the study and designed the methods. DL and ZP independently searched literatures, extracted data and assessed the quality of the included articles. Any disagreement was resolved by discussion with ZC and YY. DL completed the first version of manuscript along with the important assistance from ZC and JZ. The authors read and approved the final manuscript.

Funding
Assistance for collection of data and financial support were provided by grants from the National Natural Science Foundation of China (82070807, 91749118, 81770775, 81730022), the Planned Science and Technology Project of Hunan Province (2017TS3015) and National key research and development program (2019YFA0801903, 2019YFA0801900).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 28 August 2020 Accepted: 1 March 2021
Published online: 24 May 2021

References
1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care. 2014;38(1):31-40.
2. Teh WT, Teede HJ, Paul E, Harrison CL, Wallace EM, Allan C. Risk factors for gestational diabetes mellitus: implications for the application of screening guidelines. Aust N Z Obstet Gynaecol. 2011;51(1):26–30.
3. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676–82.
4. Hiersch L, Yoge Y. Impact of gestational hyperglycemia on maternal and child health. Curr Opin Clin Nutr Metab Care. 2014;17(3):255–60.
5. Verma A, Boney CM, Tucker R, Voel BR. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab. 2002;87(7):3227–35.
6. Khambuile L, George JA. The role of inflammation in the development of GDM and the use of markers of inflammation in GDM screening. Adv Exp Med Biol. 2019;1134:217–22.
7. Wolf M, Sauk J, Shah A, Vossen Smirnakis K, Jimenez-Kimble R, Ecker JL, Thadhani R. Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus. Diabetes Care. 2004;27(1):21–7.
8. López-Tinoco C, Roca M, García-Valero A, Muri M, Tinhones FJ, Segundo C, et al. Oxidative stress and antioxidant status in patients with late-onset gestational diabetes mellitus. Acta Diabetol. 2013;50(2):201–8.
9. Shang M, Zhao J, Yang L, Lin L. Oxidative stress and antioxidant status in women with gestational diabetes mellitus diagnosed by IADPSG criteria. Diabetes Res Clin Pract. 2015;109(1):404–10.
10. Peuchant E, Brun JL, Rigalleau V, Dubourg L, Thomas MJ, Daniel JY, et al. Oxidative and antioxidative status in pregnant women with either gestational or type 1 diabetes. Clin Biochem. 2004;37(4):293–8.
11. Grissa O, Aitgeb M, Yessoufou A, Tabka Z, Miled A, Jerbi M, et al. Antioxidant status and circulating lipids are altered in human gestational diabetes and macrosomia. Transl Res. 2007;150(3):164–71.
12. Maged AM, Torky H, Fouda MA, GadAllah SH, Waked NM, Gayed AS, et al. Role of antioxidants in gestational diabetes mellitus and relation to fetal outcome: a randomized controlled trial. J Matern-Fetal Neonatal Med. 2016;29(24):4049–54.
13. Barbagallo M, Domínguez LJ, Tagliamonte MR, Resnick LM, Paolillo G. Effects of vitamin E and glutathione on glucose metabolism: role of magnesium. Hypertension (Dallas, Tex.: 1979). 1999;34(1):102–6.

14. Foster M, Samman S. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid Redox Signal. 2010;13(10):1549–73.

15. Gommers L, Hoenderop J, Bindels R, de Baaij J. Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes. 2016;65(1):13–16.

16. Haidari F, Jalali M, Shahbazi N, Haghighizadeh M, Azadegan E. Comparison of serum levels of vitamin D and inflammatory markers between women with gestational diabetes mellitus and healthy pregnant control. J Family Reprod Health. 2016;10(1):1–8.

17. Goker Tasdemir U, Tasdemir N, Kılıç S, Abali R, Celik C, Gulemen H. Alterations of ionized and total magnesium levels in pregnant women with gestational diabetes mellitus. Gynecol Obstet Invest. 2015;79(1):19–24.

18. Asemi Z, Hashemi T, Karamali M, Samimi M, Esmailzadeh A. Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial. Am J Clin Nutr. 2013;98(6):1425–32.

19. Liu M, Jieong E, Liu H, Xie A, So E, Shi G, et al. Magnesium supplementation improves diabetic mitochondrial and cardiac diastolic function. JCI insight. 2019;4(11):e121882.

20. Asemi Z, Jamilian M, Ghasemi F, Jamilian M, Rasouli N, Mortazavi S, et al. Magnesium supplementation affects gene expression related to inflammatory, oxidative stress and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial. J Matern-Fetal Neonatal Med. 2018;32(24):4120–32.

21. Sahebi R, Rezayi M, Emadzadeh M, Salehi M, Tayefi M, Parizadeh SM, et al. The effects of vitamin D supplementation on indices of glycemic control in Iranian diabetics: a systematic review and meta-analysis. Complement Ther Clin Pract. 2019;34:294–304.

22. Sadat Najib F, Poordast T, Rezvan Nia M, Hossein DM. Effects of selenium supplementation on glucose homeostasis in women with gestational diabetes mellitus: a randomized, controlled trial. Int J Reprod Biomed. 2019;18(1):57–64.

23. Razavi M, Jamilian M, Samimi M, Ashfar Ebrahim F, Taghizadeh M, Behkadi R, et al. The effects of vitamin D and omega-3 fatty acids co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in patients with gestational diabetes. Nutr Metab. 2017;14:80.

24. Asemi Z, Karamali M, Esmailzadeh A. Effects of calcium-vitamin D co-supplementation on glycemic control, inflammation and oxidative stress in gestational diabetes: a randomized placebo-controlled trial. Diabetologia. 2014;57(9):1798–806.

25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

26. Jamilian M, Mirhosseini N, Eslahi M, Bahmani F, Shokrpour M, et al. The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. BMC Pregnancy Child. 2019;19(1):107.

27. Ostadomohammadi V, Samimi M, Mobini M, Zarezade Mehrizi M, Aghavoddin E, Chamani M, et al. The effect of zinc and vitamin E co-supplementation on metabolic status and its related gene expression in patients with gestational diabetes. J Matern-Fetal Neonatal Med. 2019;32(24):4120–7.

28. Maktabi M, Jamilian M, Amiri E, Chamani M, Asemi Z. The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes. Lipids Health Dis. 2018;17(1):163.

29. Karamali M, Bahramimoghdam S, Shafizadeh F, Asemi Z. Magnesium-zinc-calcium-vitamin D co-supplementation improves glycemic control and markers of cardiometabolic risk in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Appl Physiol Nutr Metab. 2018;43(6):565–70.

30. Jamilian M, Samimi M, Faranee AE, Aghavoddin E, Shahzad HD, Chamani M, et al. Magnesium supplementation affects gene expression related to insulin and lipid in patients with gestational diabetes. Magnes Res. 2017;30(3):71–9.

31. Karamali M, Heidarzadeh Z, Seifi SM, Samimi M, Tabassi Z, Taleee N, et al. Zinc supplementation and the effects on Pregnancy Outcomes in Gestational Diabetes: a Randomized, Double-blind, Placebo-controlled Trial. Exp Clin Endocrinol Diab. 2016;124(1):28–33.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.